---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-248760"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:35:18.718212+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma completes $30M+stock acquisition of ImmPACT Bio, gains CD19/20 CAR T candidate

## Summary
- Upfront: $30M cash (adjusted for ~$12M ImmPACT cash) plus 37.5M Lyell shares; contingent milestone shares up to 12.5M and low-single-digit royalty.
- IMPT-314 (dual-targeting CD19/20 CAR T) expected to start pivotal trial in 2025 for third-line CAR-naïve B-cell non-Hodgkin lymphoma.
- Sumant Ramachandra, former ImmPACT CEO, appointed to Lyell's Board of Directors.
- Lyell expects cash to fund operations into 2027 through clinical milestones including pivotal trial initiation for IMPT-314.

## SEC filing metadata
- accession: 0001193125-24-248760
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/0001193125-24-248760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/d901554d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-248760
- JSON: https://secwatch.observer/filing/0001193125-24-248760.json
- Plain text: https://secwatch.observer/filing/0001193125-24-248760.txt

## Key facts
- Executive change
  Sumant Ramachandra was appointed as Class III director at Lyell Immunopharma, Inc..
  - Action: appointed
  - Role: Class III director
  source text: Sumant Ramachandra, M.D., Ph.D., who was the Chief Executive Officer and a director of ImmPACT prior to the consummation of the Merger, was appointed as a Class III director to the Board of Directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/0001193125-24-248760-index.htm
- M&A Transactions
  Lyell Immunopharma, Inc. completed an acquisition involving ImmPACT Bio USA Inc. for $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock (closed 2024-10-31).
  - Action: acquisition
  - Counterparty: ImmPACT Bio USA Inc.
  - Consideration: $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock
  - Closing: 2024-10-31
  source text: Pursuant to the terms of the Merger Agreement, on the Closing Date, the Company acquired all of the outstanding equity interests of ImmPACT in exchange for an upfront payment of $30.0 million in cash (as adjusted by approximately $12.0 million for ImmPACT’s existing cash balance) and 37.5 million shares of Company Common Stock. The acquisition was effected via a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312524248760/0001193125-24-248760-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.